Post-marketing safety surveillance of pneumococcal vaccines: a real-world pharmacovigilance study using the U.S. vaccine adverse event reporting system (VAERS) database
BackgroundPneumococcal vaccines have been utilized in the United States for decades with extensive clinical safety records. However, comprehensive post-marketing pharmacovigilance evaluations for all available types remain lacking. This study aimed to assess adverse events following immunization (AE...
Saved in:
| Main Authors: | Xinkuo Zheng, Meishen Liu, Aili Ding, Shihong Zhang, Ling Wu, Fanli Kong, Weijia Sun, Yuchen Peng, Yalin Xi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Cellular and Infection Microbiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcimb.2025.1635180/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
DARE-SAFE: Denominator-Adjusted Rate Estimates of Substance Adverse Events Frequency Evaluation in Pharmaceuticals and Vaccines
by: Matthew Halma, et al.
Published: (2025-03-01) -
The safety of co-administration of recombinant zoster vaccine (Shingrix) and influenza vaccines in the elderly in VAERS during 2018–2024
by: Yihao Li, et al.
Published: (2025-12-01) -
Safety of COVID-19 vaccines
by: B. K. Romanov
Published: (2022-12-01) -
Post-marketing safety surveillance for the recombinant zoster vaccine (Shingrix), vaccine adverse event reporting system, United States, October 2017–April 2024
by: Yamin Shu, et al.
Published: (2025-02-01) -
Role of Pharmacovigilance in Drug Safety Monitoring
by: Anju E. Paul, et al.
Published: (2025-07-01)